UbiCREST technology is exclusively licensed to Boston Biochem by the laboratory of Prof. David Komander

What is UbiCREST?

The UbiCREST (Ubiquitin Chain Restriction Analysis) Deubiquitinase Enzyme Set (Catalog # K-400) is designed to analyze the ubiquitin linkages present in free polyubiquitin chains or polyubiquitin chains conjugated to a substrate protein (linked Komander paper). Eight ubiquitin linkage-specific deubiquitinases (DUBs), along with DUB reaction buffer, are included in sufficient amounts to carry out 5 UbiCREST analysis experiments. This technology is exclusively licensed to Boston Biochem by the laboratory of Dr. David Komander (read what he has to say about UbiCREST and Boston Biochem below). Learn more about UbiCREST.

UbiCREST: Developed by Ubiquitin Researchers FOR Ubiquitin Researchers

UbiCREST was developed at the Komander Laboratory at the prestigious Medical Research Council Laboratory of Molecular Biology. "We desperately need new orthogonal methods to characterise atypical ubiquitin chain types," says David Komander, Ph.D., Group Leader at the MRC Laboratory of Molecular Biology. "I am convinced that UbiCREST can have a high impact in the field, especially in conjunction with complementary methods. It should allow new insights for the still poorly characterised atypical ubiquitin chain types."

UbiCREST has already been utilized to identify and confirm the presence of atypical polyubiquitin chains on Miro1, an outer mitochondrial membrane protein whose turnover is altered in Parkinson's disease. This research was recently published in The Journal of Biological Chemistry (Birsa, N. et al. (2014) J. Biol. Chem. [Epub ahead of print]). Additionally, Emmerich et al. identified the presence of branched Lys63/Met linkages on signaling molecules via a UbiCREST approach (Emmerich et al. (2013) PNAS 110:15247 ). Through an exclusive license with Boston Biochem, UbiCREST is now available to the scientific community. "I am delighted and excited that Boston Biochem has decided to take our idea and findings to the next level, and make it available to a wider community," Adds Dr. Komander. "The Boston Biochem scientists have worked very hard to reproduce our work, and refine and optimise the method."

Scientists continue to learn more about ubiquitin and its role as a regulator of many, if not all, cellular pathways, processes, and disease states. Adds Dr. Komander, "UbiCREST is the first method to reveal and characterise heterotypic, 'branched' ubiquitin chains, and should enable us to learn about their abundance and cellular roles."

UbiCREST joins the broadest portfolio of ubiquitin research tools offered by Boston Biochem.